Search results for "Cost-benefit"

showing 10 items of 153 documents

Role of ARBs in the blood hypertension therapy and prevention of cardiovascular events

2009

Hypertension has a worldwide high incidence in the general population and undoubtedly it is the most important risk factor for cardiovascular morbidity and mortality, in industrialized countries. In this Review we investigated the role of angiotensin II receptor antagonists (ARBs) therapy in the treatment of essential hypertension. We selected in the PubMed and in a list of selected sources the most significant clinical trials and meta-analysis carried out from 1999 to now, to assess, in adult patients populations, ARBs efficacy, safety and tolerability profile, in comparison with the efficacy of the other common antihypertensive drugs, with particular regard to both the prevention of disab…

Angiotensin receptormedicine.medical_specialtyHeart DiseasesCost-Benefit AnalysisClinical BiochemistryPopulationPeptidyl-Dipeptidase AEssential hypertensionAngiotensin Receptor AntagonistsInternal medicineDrug DiscoverymedicineHumansRisk factoreducationAntihypertensive AgentsPharmacologyeducation.field_of_studyClinical Trials as TopicAngiotensin Receptor Antagonistsbusiness.industrymedicine.diseaseClinical trialCerebrovascular DisordersTreatment OutcomeTolerabilityARB blood hypertension cardiovascular eventsHeart failureHypertensionCardiologyMolecular Medicinebusiness
researchProduct

One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evalu…

2022

Antiresorptive drugs (bisphosphonates and denosumab) have become the cornerstone of medical supportive treatment of bone metastases in solid cancer patients. In the beginning, the choice of available antiresorptive agents was limited to bisphosphonates and the treatment options restricted principally to monthly pamidronate and monthly zoledronic acid. Introduction of new antiresorptive therapies (monthly denosumab) and schedules (zoledronic acid every 3 months, upfront or after initial period of monthly infusion) in the last decade increased the range of available options, thus challenging treatment decision making. Direct and indirect costs of very different treatment options are difficult…

Bone Density Conservation AgentsDiphosphonatesOsteonecrosis of the jawZoledronic acid; Denosumab; Bone metastases; Solid cancer; Osteonecrosis of the jaw; MRONJCost-Benefit AnalysisBone metastasesSolid cancerPamidronateBone NeoplasmsMRONJRisk AssessmentOncologyQuality of LifeHumansBisphosphonate-Associated Osteonecrosis of the JawDenosumabZoledronic acid
researchProduct

Cancer screening and health system resilience: Keys to protecting and bolstering preventive services during a financial crisis

2012

The aim of this paper is to elucidate the rationale for sustaining and expanding cost-effective, population-based screening services for breast, cervical and colorectal cancers in the context of the current financial crisis. Our objective is not only to promote optimal delivery of high-quality secondary cancer prevention services, but also to underline the importance of strengthening comprehensive cancer control, and with it, health system response to the complex care challenges posed by all chronic diseases. We focus primarily on issues surrounding planning, organisation, implementation and resources, arguing that given the growing cancer burden, policymakers have ample justification for e…

BudgetsCancer ResearchEconomic growthNational Health ProgramsCost-Benefit Analysismedia_common.quotation_subjectPopulationPublic policyContext (language use)Population healthFinancial managementPredictive Value of TestsNeoplasmsPreventive Health ServicesCancer screeningHumansMass ScreeningOrganizational ObjectivesMedicinePolicy Makingeducationmedia_commoneducation.field_of_studyGovernmentEvidence-Based Medicinebusiness.industryHealth PolicyEnvironmental resource managementHealth Care CostsHealth PlanningEconomic RecessionOncologyPractice Guidelines as TopicPsychological resiliencebusinessDelivery of Health CareEuropean Journal of Cancer
researchProduct

Impact of orphan drugs on Latvian budget

2016

Background Number of orphan medicinal products on the market and number of rare disease patients, taking these usually expensive products, are increasing. As a result, budget impact of orphan drugs is growing. This factor, along with the cost-effectiveness of orphan drugs, is often considered in the reimbursement decisions, directly affecting accessibility of rare disease therapies. The current study aims to assess the budget impact of orphan drugs in Latvia. Methods Our study covered a 5-year period, from 2010 to 2014. Impact of orphan drugs on Latvian budget was estimated from the National Health Service’s perspective. It was calculated in absolute values and relative to total pharmaceuti…

Budgetsendocrine systemOrphan Drug ProductionCost-Benefit AnalysisPharmacology toxicologyPharmacologyOrphan drug03 medical and health sciences0302 clinical medicineOrphan Drug ProductionOrphan drugsHumansEnzyme Replacement TherapyGenetics(clinical)Pharmacology (medical)030212 general & internal medicinehealth care economics and organizationsGenetics (clinical)ReimbursementMucopolysaccharidosis IIMedicine(all)Public economicsCost–benefit analysisResearch030503 health policy & servicesExpenditureLatvianGeneral MedicineBudget impactLatviaReimbursementlanguage.human_languageBudget impactlanguageBusiness0305 other medical scienceRare diseaseOrphanet Journal of Rare Diseases
researchProduct

Cost–benefit analysis of water-reuse projects for environmental purposes: A case study for Spanish wastewater treatment plants

2011

Water reuse is an emerging and promising non-conventional water resource. Feasibility studies are essential tools in the decision making process for the implementation of water-reuse projects. However, the methods used to assess economic feasibility tend to focus on internal costs, while external impacts are relegated to unsubstantiated statements about the advantages of water reuse. Using the concept of shadow prices for undesirable outputs of water reclamation, the current study developed a theoretical methodology to assess internal and external economic impacts. The proposed methodological approach is applied to 13 wastewater treatment plants in the Valencia region of Spain that reuse ef…

Conservation of Natural ResourcesEngineeringEnvironmental EngineeringResource (biology)Cost–benefit analysisbusiness.industryCost-Benefit AnalysisShadow priceGeneral MedicineEnvironmentManagement Monitoring Policy and LawEnvironmental economicsReuseWater PurificationSpainRecyclingSewage treatmentEconomic impact analysisDecision-makingbusinessWater resource managementWaste Management and DisposalEffluentJournal of Environmental Management
researchProduct

Economic valuation of environmental benefits from wastewater treatment processes: An empirical approach for Spain

2009

Economic research into the design and implementation of policies for the efficient management of water resources has been emphasized by the European Water Framework Directive (Directive 2000/60/EC). The efficient implementation of policies to prevent the degradation and depletion of water resources requires determining their value in social and economic terms and incorporating this information into the decision-making process. A process of wastewater treatment has many associated environmental benefits. However, these benefits are often not calculated because they are not set by the market, due to inadequate property rights, the presence of externalities, and the lack of perfect information…

Conservation of Natural ResourcesEnvironmental EngineeringCost-Benefit AnalysisShadow priceEnvironmentWaste ManagementWater SupplyEnvironmental Chemistrymedia_common.cataloged_instanceEuropean UnionEuropean unionWaste Management and DisposalEcosystemValuation (finance)media_commonCost–benefit analysisbusiness.industryWater PollutionEnvironmental resource managementPerfect informationEnvironmental economicsPollutionWater Framework DirectiveSpainProperty rightsbusinessExternalityEnvironmental MonitoringScience of The Total Environment
researchProduct

The social benefits of restoring water quality in the context of the Water Framework Directive: A comparison of willingness to pay and willingness to…

2009

The Water Framework Directive (WFD) is by far the most important piece of water legislation in Europe for the coming decades. Its main aim is to achieve "good ecological status" for all water resources by 2015. The economic valuation of the non-market benefits derived from improving water quality is an important input in assisting the design and implementation of efficient and effective water management policies. In this study, the contingent valuation method has been applied with a double purpose. On the one hand, we have estimated the value of a hypothetical improvement in water quality of a river asking individuals about their willingness to pay, and on the other hand, the issue of exemp…

Contingent valuationConservation of Natural ResourcesEnvironmental EngineeringCost–benefit analysisPresent valuebusiness.industryCost-Benefit AnalysisEnvironmental resource managementContext (language use)Environmental economicsModels TheoreticalPollutionWater resourcesWillingness to payWater Framework DirectiveRiversSocioeconomic FactorsSpainWater SupplySurveys and QuestionnairesEnvironmental ChemistryBusinessWillingness to acceptWaste Management and DisposalThe Science of the total environment
researchProduct

2016 European Guidelines on cardiovascular disease prevention in clinical practice The Sixth Joint Task Force of the European Society of Cardiology a…

2016

ABI : ankle–brachial (blood pressure) index ABPM : ambulatory blood pressure monitoring ACCORD : Action to Control Cardiovascular Risk in Diabetes ACE-I : angiotensin-converting enzyme inhibitor ACS : acute coronary syndromes ADVANCE : Action in Diabetes and Vascular disease: PreterAx

Cost-Benefit AnalysisGeneral Practice030204 cardiovascular system & hematologyGuidelineDiabete0302 clinical medicineHyperlipidemiaStakeholderMedicine030212 general & internal medicineMultiple Chronic ConditionsPractice Patterns Physicians'Societies MedicalRisk assessmenteducation.field_of_studyCardiac RehabilitationDiabetesRehabilitationSmokingPsychosocial factorAge FactorsLipidMiddle AgedPrimary carePedigreeEuropeCardiovascular DiseasesPsychosocial factorsHypertensionBlood pressureDiet HealthyRisk assessmentCardiology and Cardiovascular MedicineAdultDiagnostic Imagingmedicine.medical_specialtyAmbulatory blood pressurePopulationPopulationCardiologyHealthy lifestyleHyperlipidemiasHealth PromotionDiabetic angiopathyGuidelinesRisk Assessment03 medical and health sciencesSex FactorsDiabetes mellitusJournal ArticleHumansClinical settingsHealthy LifestyleIntensive care medicineeducationExerciseAntihypertensive AgentsNutritionAgedbusiness.industryVascular diseasePhysical activityPreventionmedicine.diseasebody regionsClinical settingBlood pressureRisk managementSocioeconomic FactorsSmoking CessationJoint Esc GuidelinesbusinessBiomarkersDiabetic Angiopathies
researchProduct

Reproducible research practices, openness and transparency in health economic evaluations: study protocol for a cross-sectional comparative analysis

2020

INTRODUCTION: There has been a growing awareness of the need for rigorously and transparent reported health research, to ensure the reproducibility of studies by future researchers. Health economic evaluations, the comparative analysis of alternative interventions in terms of their costs and consequences, have been promoted as an important tool to inform decision-making. The objective of this study will be to investigate the extent to which articles of economic evaluations of healthcare interventions indexed in MEDLINE incorporate research practices that promote transparency, openness and reproducibility. METHODS AND ANALYSIS: This is the study protocol for a cross-sectional comparative ana…

Cost-Benefit Analysisdata sharingMEDLINEcost-effectiveness analysis data sharing methodology quality reporting reproducibility03 medical and health sciencesHealth Economics0302 clinical medicineHealth careProtocolOpenness to experienceHumansMedicine17011506030212 general & internal medicinereproducibilityProtocol (science)reportingMedical educationbusiness.industry030503 health policy & servicesCost-effectiveness analysiscost-effectiveness analysisRMethodologyReproducibility of ResultsmethodologyGeneral MedicineCost-effectiveness analysisTransparency (behavior)QualityReproducibility3. Good healthEconomics MedicalData sharingCross-Sectional StudiesReportingResearch DesignqualityEconomic evaluationMedicineData sharingQuality-Adjusted Life Years0305 other medical sciencebusiness
researchProduct

Surgery for obesity.

2005

PURPOSE OF REVIEW Bariatric surgery today is the only effective therapy for morbid obesity. Commonly performed procedures include adjustable gastric banding and vertical banded gastroplasty, variations of the Roux-en-Y gastric bypass, biliopancreatic diversion or duodenal switch, and mixed procedures. This review discusses key issues in the surgical management of morbid obesity. RECENT FINDINGS The two most common bariatric procedures performed worldwide are laparoscopic adjustable gastric banding and laparoscopic Roux-en-Y gastric bypass. Controversy exists regarding the best surgical procedure. Weight loss decreases according to the procedures performed in following decreasing order: bili…

Cultural Studiesmedicine.medical_specialtyGastroplastyCost effectivenessbusiness.industrymedicine.medical_treatmentCost-Benefit AnalysisGastric BypassBariatric SurgeryPerioperativemedicine.diseaseObesityDuodenal switchEducationSurgeryMorbid obesityQuality of lifeWeight lossmedicineHumansmedicine.symptombusinessBiliopancreatic DiversionCurrent opinion in gastroenterology
researchProduct